Charles Schwab
CRBU icon

Charles Schwab’s Caribou Biosciences CRBU Stock Holding History

Charles Schwab’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
775,809
+216,167
+39% +$427K ﹤0.01% 2908
2026
Q1 		$1.06M Buy
559,642
+4,014
+0.7% +$6.89K ﹤0.01% 2891
2025
Q4 		$883K Sell
555,628
-2,846
-0.5% -$5.97K ﹤0.01% 2972
2025
Q3 		$1.3M Buy
558,474
+29,025
+5% +$54.8K ﹤0.01% 2867
2025
Q2 		$667K Sell
529,449
-197,773
-27% -$195K ﹤0.01% 3032
2025
Q1 		$664K Sell
727,222
-18,504
-2% -$24.1K ﹤0.01% 2982
2024
Q4 		$1.19M Buy
745,726
+6,196
+0.8% +$12.5K ﹤0.01% 2850
2024
Q3 		$1.45M Buy
739,530
+118,325
+19% +$242K ﹤0.01% 2798
2024
Q2 		$1.02M Sell
621,205
-203,452
-25% -$650K ﹤0.01% 2928
2024
Q1 		$4.24M Buy
824,657
+16,898
+2% +$104K ﹤0.01% 2340
2023
Q4 		$4.63M Buy
807,759
+215,910
+36% +$1.07M ﹤0.01% 2344
2023
Q3 		$2.83M Buy
591,849
+179,224
+43% +$1.11M ﹤0.01% 2495
2023
Q2 		$1.75M Buy
412,625
+2,176
+0.5% +$9.78K ﹤0.01% 2590
2023
Q1 		$2.18M Buy
410,449
+5,547
+1% +$34.5K ﹤0.01% 2504
2022
Q4 		$2.54M Buy
404,902
+6,191
+2% +$55.1K ﹤0.01% 2492
2022
Q3 		$4.21M Buy
398,711
+191,492
+92% +$1.78M ﹤0.01% 2302
2022
Q2 		$1.13M Sell
207,219
-7,326
-3% -$56K ﹤0.01% 2744
2022
Q1 		$1.97M Buy
214,545
+72,029
+51% +$759K ﹤0.01% 2652
2021
Q4 		$2.15M Buy
142,516
+9,239
+7% +$180K ﹤0.01% 2687
2021
Q3 		$3.18M Buy
+133,277
New +$3.26M ﹤0.01% 2585

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Charles Schwab's CRBU Position: Q2 2026 in Review

Charles Schwab increased its Caribou Biosciences (CRBU) stake by 39% in Q2 2026, buying an estimated $427K and bringing the position to 775,809 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2908.

Charles Schwab first reported a position in CRBU in Q3 2021 and has held it in 20 quarters since. The position peaked at $4.63M in Q4 2023. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Charles Schwab held 775,809 shares of Caribou Biosciences worth $1.37M as of Q2 2026.
  • Charles Schwab bought 216,167 Caribou Biosciences shares in Q2 2026, an estimated $427K.
  • Caribou Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2908 holding.
  • Charles Schwab first reported a position in Caribou Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Charles Schwab's Caribou Biosciences position peaked at $4.63M in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.